Endologix announced final 36-month results for the DETOUR2 study evaluating its Detour system for treating peripheral ...

Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced the final 36-month ...

The data hint at sirolimus becoming a useful option or even a replacement for paclitaxel, but full 5-year follow-up is needed ...

ANGELA STENT is Professor Emerita at Georgetown University and a Nonresident Senior Fellow at the Brookings Institution. From 2004 to 2006, she served as National Intelligence Officer for Russia and ...

November 3, 2024—The 24-month outcomes from the VIVID clinical trial, which evaluated the safety and efficacy of the Duo venous stent system (Royal Philips) for the treatment of patients with ...

A newly FDA- approved stent designed to grow with the child offers a better option.Oct. 17, 2024 ...

Bioabsorbable polymers or polymer-free technology are likely to become the preferred strategy for drug delivery from stent platforms over the next 2–3 years particularly in patients where short ...

October 29, 2024—Cook Medical announced that findings from the VIVO clinical study of the company’s Zilver Vena venous self-expanding stent demonstrated high rates of patency sustained for 3 years.

The US Food and Drug Administration has approved a heart stent specifically made for infants and young children - a device ...